OMIC Singular Genomics Systems Inc: Projected Price to Earnings
The forward P/E dynamics of Singular Genomics Systems (OMIC) demonstrate that the value has stabilized at 0.00. The issuer is implementing ESG standards by reducing manufacturing defects and toxic emissions. Innovative equipment also minimizes energy costs and reagent consumption during research. However, expansion is hindered by severe pricing pressure from industry leaders, which limits the commercial growth rate of its benchtop analysis systems.
Financial and market metric breakdowns for Singular Genomics Corp (OMIC)
- stock quotes and analyst forecast:
- company stock capitalization data:
- issuer book value statistics:
- company liabilities and liquidity data:
Debt to Equity Singular Genomics Systems|OMIC - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio Singular Genomics Systems|OMIC - Aggregate Debt Obligations|Debts to Book Capitalization Singular Genomics Systems, Inc.|OMIC - Long-Term Indebtedness|Company Short-Term Debts Singular Genomics|Quick Liquidity singulargenomics.com
- company profitability and valuation multiples indicators:
OMIC - Company Profit|Expected Profit Singular Genomics Systems|OMIC - Market Cap to Earnings|Future Price to Earnings Singular Genomics Systems Inc|OMIC - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Singular Genomics Systems, Inc.|OMIC - Operating income before deduction of amortization|Net earnings per share (EPS TTM) Singular Genomics|OMIC - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months singulargenomics.com|OMIC - Expected net earnings per share growth this year|Expected earnings per share growth for next year Singular Genomics Systems
Fundamental valuation:Singular Genomics
To qualitatively assess an asset, it is essential for an investor to compare the current market share price with the projected annual net income, which allows them to determine the extent of the premium paid for future success via the company's forward P/E multiple. This indicator reflects market expectations regarding the scaling of Singular Genomics Systems (OMIC), where profit growth driven by regular shipments of DNA sequencing reagents must justify the high multiple.
Competitor analysis
Forward P/E Multiple TEM|Qiagen NV (QGEN) - Forward Price to Earnings Multiple|Ionis Pharma - Projected Price to Earnings|Forward P/E Multiple Repligen Inc. RGEN|RNA - Future Price to Earnings|CRSP: Future Price to Earnings|WGS: Forward P/E Multiple|Ultragenyx Pharmaceutical Inc. (RARE) - Forward P/E Multiple|Future Price to Earnings Beam Therapeutics Corp|SRPT: Future Price to Earnings Multiple|Projected Price to Earnings TWST (Twist Bioscience)|TXG (10xgenomics.com) - Future Price to Earnings Multiple|Forward P/E Multiple NTLA (Intellia Therapeutics, Inc.)|Forward Price to Earnings Multiple Stoke Therapeutics Inc|BioLife Corp - Forward P/E Multiple|Projected Price to Earnings Ratio Wave Pharma|Maze Therapeutics Inc (MAZE) - Future Price to Earnings|Price to Future Earnings Ratio SION|Future Price to Earnings Prime Medicine|Projected Price to Earnings Ratio Taysha Gene Therapies Inc TSHA|Future Price to Earnings uniQure Corp (QURE)|Projected Price to Earnings MeiraGTx Corp MGTX|Forward P/E Multiple RGNX (REGENXBIO Inc.)|Market Cap to Projected Earnings solidbio.com (SLDB)|Ocugen - Forward P/E Multiple|Pacific Biosciences of California, Inc. (PACB) - Projected Price to Earnings|Benitec (BNTC) - Future Price to Earnings|DSGN - Market Cap to Projected Earnings|Projected Price to Earnings RCKT|FDMT: Future Price to Earnings Multiple|Future Price to Earnings Lexeo Therapeutics (LXEO)|Market Cap to Projected Earnings korrobio.com|Editas - Projected Price to Earnings|Silence Therapeutics Corp (SLN) - Projected Price to Earnings Ratio|PRQR - Future Price to Earnings|Market Cap to Projected Earnings Codexis, Inc. CDXS|SGMO (Sangamo Therapeutics, Inc.) - Projected Price to Earnings|NAUT: Market Cap to Future Earnings Ratio|MGX (Metagenomi, Inc) - Forward P/E Multiple|Projected Price to Earnings Ratio Precision BioSciences Inc. DTIL|Future Price to Earnings Generation Bio Co. (GBIO)|Projected Price to Earnings boundlessbio.com BOLD|Future Price to Earnings Exicure XCUR|Market Cap to Projected Earnings Imunon Inc (IMNN)|PHIO - Future Price to Earnings|Projected Price to Earnings Ratio Mustang Bio, Inc.|transcodetherapeutics.com (RNAZ) - Future Price to Earnings|Projected Price to Earnings Bionano Genomics|APDN (Applied DNA Sciences, Inc.) - Forward P/E Multiple|bluebird bio Inc. (BLUE) - Market Cap to Projected Earnings|Forward P/E Multiple IPA|Projected Price to Earnings Omega Therapeutics Corp OMGA|Forward P/E Multiple RGLS (Regulus Therapeutics)|SYRS: Price to Future Earnings Ratio|TBIO - Future Price to Earnings|TCON (TRACON Pharmaceuticals Inc.) - Price to Future Earnings Ratio|UBX: Forward P/E Multiple
